Supernus Pharmaceuticals (SUPN) Capital Expenditures (QoQ) (2011 - 2025)
Supernus Pharmaceuticals (SUPN) Capital Expenditures (QoQ) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 231.01% |
| Sep 30, 2025 | -71.65% |
| Jun 30, 2025 | 39.14% |
| Mar 31, 2025 | 53.52% |
| Dec 31, 2024 | 6.50% |
| Sep 30, 2024 | 212.50% |
| Jun 30, 2024 | -74.19% |
| Mar 31, 2024 | 788.89% |
| Dec 31, 2023 | -124.00% |
| Sep 30, 2023 | -5.66% |
| Jun 30, 2023 | -42.81% |
| Mar 31, 2023 | 265.48% |
| Jun 30, 2022 | -94.35% |
| Dec 31, 2020 | 32.72% |
| Mar 31, 2020 | -2.24% |
| Dec 31, 2019 | 2,595.19% |
| Sep 30, 2019 | -312.24% |
| Jun 30, 2019 | -75.00% |
| Mar 31, 2019 | 104.17% |
| Dec 31, 2018 | -76.35% |